ArticleDiscover oncology2025
Construction of a multimodal esophageal cancer prognostic model with screening of key genes and investigation of their biological functions.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeDespite decreased esophageal carcinoma incidence, its prognosis remains challenging. We aimed to develop a multimodal prognostic model to optimize treatment strategies and elucidate biological mechanisms of key regulatory genes.
methodsPivotal prognostic genes were screened using integrated bioinformatics and immunohistochemistry. A multimodal model combining PET/CT radiomics (metabolic tumor volume, SUV), clinicopathological parameters (lymph node metastasis, differentiation grade, infiltration depth), and molecular biomarkers was established and validated. Functional experiments and co-immunoprecipitation/transcriptomic sequencing explored biological roles and molecular networks.
resultsCASQ2 emerged as a key prognostic gene. The validated model integrated CASQ2 expression, radiomic features (MTV/SUV), and clinical staging, demonstrating high predictive accuracy. Functional assays confirmed that CASQ2 overexpression enhanced esophageal cancer cell proliferation and invasion. Mechanistically, CASQ2 activated AKT/PI3K signaling and disrupted calcium homeostasis, with protein interaction and transcriptomic analyses delineating its regulatory network.
conclusionWe established a multimodal prognostic model incorporating molecular, radiomic, and clinical parameters, and identified CASQ2 as a critical regulator of esophageal carcinogenesis. CASQ2 likely drives tumor progression through AKT/PI3K signaling and calcium pathway dysregulation, offering dual therapeutic targets. This integrative approach advances personalized prognosis prediction and mechanistic understanding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.